Autopsy report · NCT05781360

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0237 in Adult Participants with Advanced Solid Tumors

“An internal business decision, not based on safety or regulatory considerations.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 3 months before it stopped.
• 192 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Jiangsu Simcere Pharmaceutical Co., Ltd.

Sponsor type

Industry

Conditions

Locally Advanced Unresectable or Metastatic Solid Tumor

Interventions

SIM0237

Participants

192

Sites

9

Countries

China, United States

Trials that died the same way

• A Phase 1 Study of ADA-011 for Subjects With Advanced Solid Tumors
  “Internal company decision (non-safety related)” (81% match in meaning)
• Study of Poziotinib in Japanese Patients With NSCLC
  “Business decision, not related to safety.” (79% match in meaning)
• A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UCB8600 in Healthy Participants, Atopic Participants, and Chronic Spontaneous Urticaria Participants
  “internal company decision; not safety related” (78% match in meaning)
• A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
  “business decision, not safety reasons.” (74% match in meaning)
• Clinical Performance Evaluation of the Hativ P30
  “Company's internal decision.” (73% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.